Myocea

Executive Summary

Myocea is a San Diego-based biotechnology company developing therapies for skeletal muscle disorders, with a focus on facioscapulohumeral muscular dystrophy (FSHD). The company leverages a proprietary platform to differentiate pluripotent and embryonic stem cells into functional skeletal muscle progenitors and tissues, enabling disease modeling, drug discovery, and regenerative medicine applications. FSHD is a progressive genetic disorder with no approved therapies, representing a significant unmet medical need. Myocea's lead program aims to address this by targeting the underlying pathophysiology, potentially halting or reversing muscle degeneration. The company's platform has broader applicability beyond FSHD, including other muscle-wasting diseases and tissue repair. As a pre-clinical stage company, Myocea is advancing its FSHD program through in vivo validation and IND-enabling studies. Success would not only provide a first-in-class treatment for FSHD but also validate the platform for additional indications. While still early-stage, the science is compelling and the market opportunity is substantial. Upcoming milestones include completion of in vivo efficacy studies and preparation for regulatory filings, with potential partnerships to accelerate development.

Upcoming Catalysts (preview)

• Q4 2026Completion of in vivo efficacy data for FSHD lead program50% success
• H1 2027IND-enabling study initiation40% success
• TBDPotential strategic partnership or licensing deal30% success